Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist - 2nd communication: Lack of central nervous system and cardiovascular effects

Arzneimittel-Forschung/Drug Research

Volumn 50, Issue 5, 2000, Pages 441-448

  Kreutner, William ^a   Hey, John A ^a   Chiu, Peter ^a   Barnett, Allen ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CAS 100643 71 8; CAS 79794 75 5; Claritin ; Desloratadine, sedation, studies of cardiovascular and central nervous effects

Indexed keywords

DESLORATADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LORATADINE;

ALLERGY; ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR EFFECT; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; GUINEA PIG; HUMAN; MALE; MOUSE; XENOPUS LAEVIS;

EID: 0034111253     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300228     Document Type: Article

References (14)

1. [1] Slater, J. W., Zechnich, A. D., Haxby, D. G., Second-generation antihistamines: a comparative review. Drugs 57, 31 (1999)
2. [2] Woosley, R. L., Chen, Y., Freiman, J. P. et al., Mechanism of the cardiotoxic actions of terfenadine. JAMA 269, 1532 (1993)
3. [3] Davies, A. J., Harindra, V., McEwan, A. et al., Cardiotoxic effect with convulsions in terfenadine overdose. Br. Med. J. 298, 325 (1989)
4. [4] Monahan, B. P., Ferguson, C. L., Killeavy, E. S. et al., Torsades de pointes occurring in association with terfenadine use. JAMA 264, 2788 (1990)
5. [5] MacConnell, T. J., Stanners, A. J., Torsades de pointes complicating treatment with terfenadine. Br. Med. J. 302, 1469 (1991)
6. [6] Zimmermann, M., Duruz, H., Guinand, O. et al., Torsades de pointes after treatment with terfenadine and ketoconazole. Eur. Heart J. 13, 1002 (1992)
7. [7] Zechnich, A. D., Haxby, D. G., Drug interactions associated with terfenadine and related nonsedating antihistamines. West. J. Med. 164, 68 (1996)
8. [8] Honig, P. K., Woosley, R. L., Zamam, K. et al., Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin. Pharmacol. Ther. 52, 231 (1992)
9. [9] Craft, T.M., Torsades de pointes after astemizole overdose. Br. Med. J. (Clin. Res. Ed.) 292, 660 (1986)
10. 1 receptor antagonist. 1st Communication: Receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneim. Forsch./Drug Res. 50 (I), 345 (2000)
11. [11] Barnett, A., Iorio, L. C., Kreutner, W. et al., Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine. Agents Actions 14, 590 (1984)
12. 1 antagonists: comparative studies with loratadine, terfenadine and sedating antihistamines in guinea-pigs. Clin. Exp. Allergy 25, 974 (1995)
13. [13] Caballero, R., Delpón, E., Valenzuela, C. et al., Effect of descarboethoxyloratadine, the major metabolite of loratadine, on the human cardiac potassium channel Kvl.5. Br. J. Pharmacol. 122, 796 (1997)
14. + channels. J. Cardiovasc. Pharmacol. 30, 42 (1997)